English
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Bulgarian
Catalan
Cebuano
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
English
Esperanto
Estonian
Filipino
Finnish
French
Frisian
Galician
Georgian
German
Greek
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Khmer
Korean
Kurdish (Kurmanji)
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Samoan
Scottish Gaelic
Serbian
Sesotho
Shona
Sindhi
Sinhala
Slovak
Slovenian
Somali
Spanish
Sudanese
Swahili
Swedish
Tajik
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
Patent, ine musoro unoti "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated PTSD," yakanangidzirwa kune zvinyorwa zvitsva uye nzira dzekuongorora PTSD pamwe nekurapa PTSD mushure mekuongororwa kwakadaro.
"Mushonga unochengetedzwa nemvumo iyi unobva kune imwe yemakirasi akatevedzana ari kugadzirwa neNeurovation Labs kuti igone kuvhenekwa nechinangwa chePTSD uye kuongorora zviri nani nzira dziri pasi pePTSD uye kumwe kusagadzikana kwehutano hwepfungwa. Mishonga iyi uye nzira dzinoenderana dzakafukidzwa nemvumo inomiririra chinyorwa, nzira yakanangwa yehutano hwepfungwa uye kuona kuvhiringidzika kwehuropi, "akadaro Dr. Jennifer Perusini, Co-Founder & Chief Executive Officer wekambani.
Patent iyi ndeye Neurovation Labs chete uye ndiyo yekutanga kuburitswa kubva kune yakafaranuka pfuma portfolio kubva mukutsvagisa nekusimudzira kwekambani.
